Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Evaluation of Relationship between Minimal Residual Disease (MRD) and Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) Using Quantitative Fluorescent PCR

The relation between end of induction minimal residual disease and different risk factors in patients with acute lymphoblastic leukemia

Background: Malignant disorder with B or T stem cell basis leads to development and continuation of acute lymphoblastic leukemia (ALL) due to aggregation of blast cells in bone marrow. The environmental, genetic, and demographic factors may influence the disease relapse. The objective of this study was to assess the relation between end of induction minimal residual disease and different risk f...

Chronic lymphocytic leukemia and Hodgkin's disease. Clinicopathologic study of three cases with good prognosis.

1. Reiter A, Schrappe M, Luwdig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84:3122-33. 2. Wan JH, Trainor KJ, Brisco MJ, Morley AA. Monoclonality in B-cell lymphoma detected in paraffin wax embedded using the polymerase chain reaction. J Clin Pathol 1990; 43:888-90. 3. Brisco...

TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia

Acquired drug resistance in childhood T-cell acute lymphoblastic leukemia (T-ALL) remains a significant clinical problem. In this study, a novel gene therapy target for childhood T-ALL to overcome chemoresistance was discovered: TFDP3 increased in the minimal residual disease (MRD) positive childhood T-ALL patients. Then, we established a preclinical model of resistance to induction therapy to ...

Evaluation of bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia

Background: The purpose of this study was to evaluate long-term changes in bone density profile among survivors of childhood acute lymphoblastic leukemia. Patients and Methods: This was a 5 year prospective study comprised of thirty-one survivors of childhood acute lymphoblastic leukemia with a mean age of 11.8 (4.6) years, who completed therapy at least 1 year previously (according to the ...